The use of recombinant factor VIIa (rFVIIa) in people with haemophilia who develop inhibitors
NHS Quality Improvement Scotland
Record ID 32007000449
English
Authors' recommendations:
Key Points
It is clinically proven that rFVIIa is a safe and effective treatment for the control of bleeding and management of perioperative haemostasis in people with haemophilia and inhibitors.
A guideline from the UK Haemophilia Centre Doctors Organisation (UKHCDO) makes recommendations for appropriate use of rFVIIa in the indications for which it is licensed. The standard dose is considered to be 90;120 Dg/kg given as a bolus every 2;3 hours until cessation of bleeding.
Further clinical trials are required to compare the present standard dose with higher dose regimens of rFVIIa.
Prophylactic use of rFVIIa is costly because high doses require to be given frequently.
Details
Project Status:
Completed
URL for project:
http://www.nhshealthquality.org/nhsqis/3532.html
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Scotland
MeSH Terms
- Factor VIIa
- Hemophilia A
Contact
Organisation Name:
Quality Improvement Scotland
Contact Address:
Delta House, 50 West Nile Street Glasgow G1 2NP Scotland United Kingdom Tel: +44 141 225 6988; Fax: +44 141 221 3262
Contact Name:
shtg.hcis@nhs.net
Contact Email:
shtg.hcis@nhs.net
Copyright:
NHS Quality Improvement Scotland (NHS QIS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.